In the prescription information for FDA-approved CAR-Ts that are listed in Table 1, the only IL6-directed therapy mentioned for the treatment of CAR-T-induced CRS is Tocilizumab (anti-IL6R). The gene discussed is IL6; the disease is congenital rubella syndrome.